Singapore, Sept. 09, 2022 (GLOBE NEWSWIRE) — Conclusions of the Global Peptide Therapeutics and Clinical Trials Insight 2028 report:
- Global Peptide Therapeutics Market Opportunity >USD 75 Billion by 2028
- Overview of Peptide Therapeutics Global Clinical Trials by Company, Indication and Phase
- Peptide therapeutics in clinical trials: > 800 drugs
- Peptide Therapeutics commercially available on the market: > 200 drugs
- Overview of Global Peptide Therapeutics Clinical Trials by Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioids, Depsipeptides, Neuropeptides, Natriuretics, Bicyclic Peptides
Download sample report: https://www.kuickresearch.com/ccformE.php?t=1650627251
In recent years, there has been a rapid search for the development of new cancer therapies that have the ability to specifically target cancer cells. The researchers’ widespread efforts have allowed them to utilize the therapeutic potential of peptides in cancer management. So far, several peptide drugs have entered the market and shown immense response in cancer treatment. Given their small size, peptides have the ability to penetrate deeper into the target tissue and induce a robust anti-tumor response. Moreover, the ease of manufacturing peptides has also attracted a lot of interest from pharmaceutical companies.
Technological advancements in the field of biotechnology have led to the development of several new approaches for using peptides as therapeutic molecules, including peptide vaccines, peptide drug conjugates, anticancer peptides, bifusion proteins, and others. These are relatively new molecules that are mostly present in clinical development and are expected to see an encouraging response in the market during the forecast period. Currently, Riavax (GV1001) developed by GemVax and Kael is the only vaccine to have obtained marketing authorization in South Korea for the treatment of pancreatic cancer. The rapid approval of this vaccine encouraged pharmaceutical investments in this sector. The pipeline of new peptide cancer vaccines is very crowded and several product launches are expected in the coming years.
One of the most advanced peptide cancer vaccines in development is NeuVax, which is composed of the E75 (nelippimut-S) peptide derived from human epidermal growth factor receptor 2 (HER2) combined with colony-stimulating factor of macrophage granulocytes (GM-CSF) as an immunoadjuvant. E75 is a major histocompatibility complex (MHC) class I epitope that stimulates a CD8+ cytotoxic T cell (CTL) response. Imugene has also developed Her-Vaxx, a B-cell cancer peptide immunotherapy designed to target breast cancer tumors that express Her2.
Moreover, other approaches are also entering clinical development which will drive its growth in the market. For example, in 2022, the US FDA also accepted the IND application for LTX-315 to initiate a phase II clinical trial in the first quarter of 2022. LTX-315 is a potential first-in-class oncolytic peptide to which one accesses for the management of basal cell carcinoma. . The technology is based on pioneering research into host defense peptides – nature’s first line of defense against foreign pathogens. The investigational drug has shown encouraging tumor-specific immune cellular responses in multi-indication Phase I/II oncology trials.
Combination therapies are also expected to transform the global cancer peptide therapy market with improved survival outcomes and large number of ongoing clinical trials. For example, Pepscan received Investigational New Drug (IND) approval to evaluate its personalized neo-antigen peptide vaccine in combination with pembrolizumab for the treatment of advanced solid tumors. The company will provide its personalized peptide vaccine to six patients in a Mayo Clinic-led Phase I clinical trial. In addition, Endevica Bio also received IND approval for TCMCB07, an investigational melanocortin-4 antagonist peptide designed to treat cachexia in people with cancer. The company plans to initiate a phase II clinical trial in pancreatic cancer in the second quarter of 2023.
According to the findings of our report, the global market for peptide cancer therapies is expected to surpass US$75 billion by 2028, which is primarily attributed to the rising prevalence of cancer worldwide and the increase in prescribing peptide therapies for cancer management. The cancer therapeutic peptides market is moderately competitive with several key players including Amgen, Eli Lilly, Takeda Pharmaceutical, Pfizer, Roche, Bachem Holdings and several others. Huge investments by pharmaceutical companies and the presence of a strong clinical drug pipeline are also expected to boost the market growth over the forecast period.